# Synthesis and Evaluation of Novologues as C-Terminal Hsp90 Inhibitors with Cytoprotective Activity against Sensory Neuron Glucotoxicity

Bhaskar Reddy Kusuma<sup>§</sup>, Liang Zhang<sup>#</sup>, Teather Sundstrom<sup>§</sup>, Laura B. Peterson<sup>§</sup>, Rick T.

Dobrowsky<sup>#</sup> and Brian S. J.  $Blagg^{\$^*}$ 

<sup>§</sup>Departments of Medicinal Chemistry and <sup>#</sup> Pharmacology and Toxicology

The University of Kansas, Lawrence, KS 66045

\* Correspondence should be addressed to: Brian S. J. Blagg, Department of Medicinal

Chemistry, 4070 Malott Hall, 1251 Wescoe Hall Dr., The University of Kansas, Lawrence, KS 66045, bblagg@ku.edu.

### List of Contents

<sup>1</sup> H and <sup>13</sup> C NMR spectrums for all new compounds	S2-S92
HPLC analytical traces for compounds 13b, 13f, 13i, 13h, and 13n	S93-S97





















Supporting information







Supporting information

































Supporting information










































S51











Supporting information























Supporting information


































Supporting information







Supporting information









S91





Analytical reverse-phase HPLC profile of compound **13b** prior to bioassay. Retention time = 6.401 min. Purity ~ 95%. Absorbance wavelength = 214 nm.



Analytical reverse-phase HPLC profile of compound **13f** prior to bioassay. Retention time = 7.631 min. Purity ~ 97%. Absorbance wavelength = 214 nm.



Analytical reverse-phase HPLC profile of compound **13h** prior to bioassay. Retention time = 7.465 min. Purity ~ 95%. Absorbance wavelength = 214 nm.



Analytical reverse-phase HPLC profile of compound **13i** prior to bioassay. Retention time = 5.057 min. Purity ~ 96%. Absorbance wavelength = 214 nm.



Analytical reverse-phase HPLC profile of compound **13n** prior to bioassay. Retention time = 4.384 min. Purity ~ 98%. Absorbance wavelength = 214 nm.